Figure 5 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

<p>Dual targeting of Bcl-xL and Mcl-1 leads to synergistic decreases in cell viability in 3D LNCaP95 spheroids and the LuCaP 167CR organoid model. Dual treatment of navitoclax and A-1331852 with S63845 in 3D prostate cancer models. <b>A,</b> Representative images for each treatment condition before treatment and 24, 48, and 72 hours after treatment. <b>B</b> and <b>C,</b> Viability of spheroids measured by 3D CellTiter-Glo after 72 hours of treatment. Plots show mean ± SD. ****, <i>P</i> < 0.0001. LuCaP-167CR organoids were treated with the combination of A-1331852 and S63845 (<b>D–F</b>) or navitoclax and S63845 (<b>G–I</b>). Drug curves (<b>D</b> and <b>G</b>) show mean ± SD. Dose–response matrices (<b>E</b> and <b>H</b>) and Bliss synergy plots (<b>F</b> and <b>I</b>) were generated using the Synergyfinder+ R package to evaluate synergy. All spheroid experiments were completed in triplicate. Organoid experiments had six technical replicates with three biological replicates.</p>

Authors

Publication Details

Published
2025-08-21
DOI
https://doi.org/10.1158/2767-9764.29957555
Primary Topic
Cell Adhesion Molecules Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Figure 5 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

Kelli M. Wilson, Erin Beck, Andres F. Leon, Craig J. Thomas et al.
Cell Adhesion Molecules Research
article

Figure 5 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

Kelli M. Wilson, Erin Beck, Andres F. Leon, Craig J. Thomas, Kinjal Bhadresha, Xiaohu Zhang, Keith Thomas Schmidt, Jessica D. Kindrick, Adam G. Sowalsky, Carleen Klumpp‐Thomas, Michele Ceribelli, Erica L. Beatson, Crystal McKnight, Giulia C. Napoli, Douglas K. Price, William D. Figg, Emily N. Risdon, JuanJuan Yin, Cindy H. Chau, Benjamin C. Brim
article en

Abstract

<p>Dual targeting of Bcl-xL and Mcl-1 leads to synergistic decreases in cell viability in 3D LNCaP95 spheroids and the LuCaP 167CR organoid model. Dual treatment of navitoclax and A-1331852 with S63845 in 3D prostate cancer models. <b>A,</b> Representative images for each treatment condition before treatment and 24, 48, and 72 hours after treatment. <b>B</b> and <b>C,</b> Viability of spheroids measured by 3D CellTiter-Glo after 72 hours of treatment. Plots show mean ± SD. ****, <i>P</i> < 0.0001. LuCaP-167CR organoids were treated with the combination of A-1331852 and S63845 (<b>D–F</b>) or navitoclax and S63845 (<b>G–I</b>). Drug curves (<b>D</b> and <b>G</b>) show mean ± SD. Dose–response matrices (<b>E</b> and <b>H</b>) and Bliss synergy plots (<b>F</b> and <b>I</b>) were generated using the Synergyfinder+ R package to evaluate synergy. All spheroid experiments were completed in triplicate. Organoid experiments had six technical replicates with three biological replicates.</p>

Openalex Percentile: Top 71%
Cell Adhesion Molecules Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.